Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 768 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for... July 1, 2022 Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline... August 31, 2026 Becoming My Own Advocate While Living With a Rare Cancer: A... April 27, 2023 Ahead of key Competitiveness Council Meeting of European Research Ministers, ESMO... May 26, 2026 Load more HOT NEWS Hormone therapy gets green light for advanced prostate cancer EMA Recommends Granting a Conditional Marketing Authorisation for Loncastuximab Tesirine FDA Approves Zidesamtinib for ROS1-positive Non-Small Cell Lung Cancer Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite...
